DelveInsight’s Thrombotic Thrombocytopenic Purpura market report thoroughly explains the Thrombotic Thrombocytopenic Purpura historical and forecasted epidemiology and the Thrombotic Thrombocytopenic Purpura market trends in the 7MM.
Key Takeaways from the Thrombotic Thrombocytopenic Purpura Market Report
-
According to Borborema et al. (2020), the Oklahoma TTP-HUS registry, representing a population base of 2 million individuals has found a family with cTTP every 26 years.
-
According to Chiasakul and Cuker (2018), iTTP is extremely rare – it is estimated that only 5% of all cases of TTP are inherited. In contrast, aTTP accounts for approximately 95% of all cases of TTP.
-
The leading companies in the Thrombotic Thrombocytopenic Purpura market include Takeda, Omeros Corporation, and others.
-
Key Thrombotic Thrombocytopenic Purpura therapies in the pipeline include TAK-755 (BAX930/SHP655), Narsoplimab (OMS721), and others.
-
Takeda’s TAK-755 (BAX930/SHP655) is a human recombinant ADAMTS13, a plasma metalloprotease that regulates von Willebrand Factor (VWF) multimers. The drug is intended to be an alternative to the current ADAMTS13 replacement, which uses large volumes of fresh frozen plasma containing variable amounts of ADAMTS13 and typically takes two hours or more to prepare and infuse.
-
Narsoplimab (OMS721) by Omeros Corporation is an intravenous human monoclonal antibody that targets mannan-binding lectin-associated serine protease-2 (MASP-2), an effector enzyme of the complement system’s lectin pathway.
Request for a sample to know more @ Thrombotic Thrombocytopenic Purpura Market Outlook
Thrombotic Thrombocytopenic Purpura: Overview
Thrombotic Thrombocytopenic Purpura (TTP), first identified by Singer in 1947, is a rare and life-threatening thrombotic microangiopathy characterised by microangiopathic hemolytic anaemia, severe thrombocytopenia, and organ ischemia linked to disseminated microvascular platelet rich-thrombi.
Thrombotic Thrombocytopenic Purpura Epidemiology Segmentation
The Thrombotic Thrombocytopenic Purpura report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
-
Thrombotic Thrombocytopenic Purpura Total Diagnosed Prevalent Cases
-
Thrombotic Thrombocytopenic Purpura Type Specific Prevalent Cases
-
Acquired Thrombotic Thrombocytopenic Purpura Age-Specific Diagnosed Prevalent Cases
-
Acquired Thrombotic Thrombocytopenic Purpura Gender-Specific Diagnosed Prevalent Cases
-
Congenital Thrombotic Thrombocytopenic Purpura Age-Specific Diagnosed Prevalent Cases
-
Congenital Thrombotic Thrombocytopenic Purpura Gender-Specific Diagnosed Prevalent Cases
Thrombotic Thrombocytopenic Purpura Treatment Landscape
The current TTP treatment options include Plasma therapy, immunosuppressive therapy, and Glucocorticosteroids. Some FDA-approved drugs such as Rituximab, Octaplas, and others are also used in the TTP treatment.
Thrombotic Thrombocytopenic Purpura Market Outlook
The Thrombotic Thrombocytopenic Purpura market size is anticipated to grow due to pharmaceutical companies’ extensive research and development activities and upcoming therapies such as TAK-755 (BAX930/SHP655), Narsoplimab (OMS721), and others during the forecast period (2021-30).
Get a detailed analysis of the market @ Thrombotic Thrombocytopenic Purpura Market Analysis
Thrombotic Thrombocytopenic Purpura Pipeline Therapies and Key Companies
-
TAK-755 (BAX930/SHP655): Takeda
-
Narsoplimab (OMS721): Omeros Corporation
Table of Contents
|
1. |
Key Insights |
|
2. |
Report Introduction |
|
3. |
Thrombotic Thrombocytopenic Purpura (TTP) Market Overview at a Glance |
|
4. |
Thrombotic Thrombocytopenic Purpura Market: Future Perspective |
|
5. |
Executive Summary of Thrombotic Thrombocytopenic Purpura (TTP) |
|
6. |
Key Events |
|
7. |
TTP Disease Background and Overview |
|
8. |
TTP Treatment and Management |
|
9. |
TTP Epidemiology and Patient Population |
|
10. |
TTP Patient Journey |
|
11. |
TTP Marketed Drugs |
|
12. |
TTP Emerging Drugs |
|
13. |
Thrombotic Thrombocytopenic Purpura (TTP): 7MM Market Analysis |
|
14. |
7MM Thrombotic Thrombocytopenic Purpura (TTP): Country-Wise Market Analysis |
|
15. |
KOL Views |
|
16. |
TTP Market Drivers |
|
17. |
TTP Market Barriers |
|
18. |
SWOT Analysis |
|
19. |
TTP Unmet Needs |
|
20. |
TTP Reimbursement and Market Access |
|
21. |
Appendix |
|
22. |
DelveInsight Capabilities |
|
23. |
Disclaimer |
|
24. |
About DelveInsight |
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Acquired Thrombotic Thrombocytopenic Purpura Pipeline Insight
“Acquired Thrombotic Thrombocytopenic Purpura Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acquired Thrombotic Thrombocytopenic Purpura market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/